Molecular Net Working Capital vs Net Receivables Analysis

MTEM Stock

USD 0.40 0.06 17.65%

Molecular Templates financial indicator trend analysis is infinitely more than just investigating Molecular Templates recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Molecular Templates is a good investment. Please check the relationship between Molecular Templates Net Working Capital and its Net Receivables accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Templates. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.

Net Working Capital vs Net Receivables

Net Working Capital vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Molecular Templates Net Working Capital account and Net Receivables. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Molecular Templates' Net Working Capital and Net Receivables is 0.15. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Molecular Templates, assuming nothing else is changed. The correlation between historical values of Molecular Templates' Net Working Capital and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Molecular Templates are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Net Working Capital i.e., Molecular Templates' Net Working Capital and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.15

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Working Capital

Net Receivables

Most indicators from Molecular Templates' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Molecular Templates current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Templates. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.At this time, Molecular Templates' Issuance Of Capital Stock is very stable compared to the past year. As of the 26th of November 2024, Enterprise Value Over EBITDA is likely to grow to 12.85, while Tax Provision is likely to drop about 18.7 K.

Molecular Templates fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Long Term Debt Total	Current Deferred Revenue	Short Term Debt	Common Stock Total Equity	Common Stock	Other Liab
Total Assets		0.35	0.77	0.62	0.62	-0.32	0.1	0.18	0.64	0.84	0.86	0.98	0.29	0.69	0.49	0.37	0.2	0.63	0.21	0.98	0.52	0.61	0.42	0.04	0.31	0.75
Other Current Liab	0.35		0.47	-0.14	0.44	0.53	-0.46	0.38	-0.34	0.25	0.49	0.34	0.21	0.71	0.54	0.55	0.5	0.58	0.16	0.35	0.54	0.27	-0.37	0.41	0.4	0.41
Total Current Liabilities	0.77	0.47		0.2	0.76	0.07	-0.31	0.02	0.38	0.75	0.78	0.71	0.57	0.56	0.55	0.71	0.46	0.78	0.46	0.72	0.84	0.93	0.2	0.19	0.25	0.66
Total Stockholder Equity	0.62	-0.14	0.2		0.38	-0.68	0.53	0.15	0.83	0.66	0.49	0.62	0.18	0.08	-0.35	0.07	-0.2	-0.21	0.13	0.56	0.0	0.1	0.64	-0.23	-0.02	0.43
Property Plant And Equipment Net	0.62	0.44	0.76	0.38		0.13	-0.24	0.11	0.33	0.77	0.79	0.53	0.83	0.38	0.19	0.72	0.36	0.43	0.78	0.51	0.72	0.62	0.42	0.07	-0.1	0.81
Net Debt	-0.32	0.53	0.07	-0.68	0.13		-0.67	-0.06	-0.85	-0.27	0.04	-0.31	0.2	0.32	0.31	0.35	0.5	0.28	0.19	-0.31	0.49	0.12	-0.54	0.38	0.14	0.14
Retained Earnings	0.1	-0.46	-0.31	0.53	-0.24	-0.67		0.0	0.52	0.12	0.01	0.13	-0.42	-0.27	-0.37	-0.45	-0.89	-0.43	-0.44	0.09	-0.51	-0.33	0.19	-0.83	-0.27	-0.19
Accounts Payable	0.18	0.38	0.02	0.15	0.11	-0.06	0.0		0.02	0.25	0.25	0.16	-0.02	0.18	0.1	-0.11	0.07	0.08	0.02	0.15	-0.06	-0.15	-0.08	0.08	0.05	0.18
Cash	0.64	-0.34	0.38	0.83	0.33	-0.85	0.52	0.02		0.67	0.39	0.6	0.18	-0.09	-0.19	0.05	-0.25	-0.02	0.12	0.58	0.02	0.33	0.7	-0.32	-0.07	0.25
Non Current Assets Total	0.84	0.25	0.75	0.66	0.77	-0.27	0.12	0.25	0.67		0.8	0.74	0.6	0.36	0.19	0.59	0.13	0.41	0.49	0.72	0.53	0.64	0.39	-0.14	-0.08	0.71
Non Currrent Assets Other	0.86	0.49	0.78	0.49	0.79	0.04	0.01	0.25	0.39	0.8		0.85	0.42	0.73	0.42	0.47	0.25	0.58	0.33	0.82	0.74	0.64	0.32	0.01	0.27	0.87
Cash And Short Term Investments	0.98	0.34	0.71	0.62	0.53	-0.31	0.13	0.16	0.6	0.74	0.85		0.16	0.74	0.49	0.27	0.19	0.6	0.09	0.99	0.49	0.55	0.4	0.07	0.42	0.73
Common Stock Shares Outstanding	0.29	0.21	0.57	0.18	0.83	0.2	-0.42	-0.02	0.18	0.6	0.42	0.16		0.05	-0.01	0.77	0.39	0.25	0.97	0.15	0.55	0.55	0.25	0.09	-0.43	0.61
Short Term Investments	0.69	0.71	0.56	0.08	0.38	0.32	-0.27	0.18	-0.09	0.36	0.73	0.74	0.05		0.77	0.29	0.45	0.76	0.01	0.75	0.6	0.41	-0.08	0.36	0.58	0.7
Non Current Liabilities Total	0.49	0.54	0.55	-0.35	0.19	0.31	-0.37	0.1	-0.19	0.19	0.42	0.49	-0.01	0.77		0.19	0.38	0.95	-0.02	0.56	0.46	0.44	-0.23	0.28	0.4	0.4
Other Current Assets	0.37	0.55	0.71	0.07	0.72	0.35	-0.45	-0.11	0.05	0.59	0.47	0.27	0.77	0.29	0.19		0.51	0.42	0.62	0.26	0.71	0.68	-0.09	0.23	-0.05	0.45
Other Stockholder Equity	0.2	0.5	0.46	-0.2	0.36	0.5	-0.89	0.07	-0.25	0.13	0.25	0.19	0.39	0.45	0.38	0.51		0.45	0.38	0.21	0.62	0.42	0.01	0.92	0.49	0.35
Total Liab	0.63	0.58	0.78	-0.21	0.43	0.28	-0.43	0.08	-0.02	0.41	0.58	0.6	0.25	0.76	0.95	0.42	0.45		0.21	0.66	0.65	0.68	-0.1	0.28	0.35	0.55
Property Plant And Equipment Gross	0.21	0.16	0.46	0.13	0.78	0.19	-0.44	0.02	0.12	0.49	0.33	0.09	0.97	0.01	-0.02	0.62	0.38	0.21		0.08	0.44	0.42	0.31	0.12	-0.48	0.6
Total Current Assets	0.98	0.35	0.72	0.56	0.51	-0.31	0.09	0.15	0.58	0.72	0.82	0.99	0.15	0.75	0.56	0.26	0.21	0.66	0.08		0.47	0.54	0.39	0.1	0.43	0.71
Short Long Term Debt Total	0.52	0.54	0.84	0.0	0.72	0.49	-0.51	-0.06	0.02	0.53	0.74	0.49	0.55	0.6	0.46	0.71	0.62	0.65	0.44	0.47		0.84	0.05	0.35	0.36	0.65
Current Deferred Revenue	0.61	0.27	0.93	0.1	0.62	0.12	-0.33	-0.15	0.33	0.64	0.64	0.55	0.55	0.41	0.44	0.68	0.42	0.68	0.42	0.54	0.84		0.13	0.15	0.2	0.53
Short Term Debt	0.42	-0.37	0.2	0.64	0.42	-0.54	0.19	-0.08	0.7	0.39	0.32	0.4	0.25	-0.08	-0.23	-0.09	0.01	-0.1	0.31	0.39	0.05	0.13		0.02	0.04	0.36
Common Stock Total Equity	0.04	0.41	0.19	-0.23	0.07	0.38	-0.83	0.08	-0.32	-0.14	0.01	0.07	0.09	0.36	0.28	0.23	0.92	0.28	0.12	0.1	0.35	0.15	0.02		0.63	0.12
Common Stock	0.31	0.4	0.25	-0.02	-0.1	0.14	-0.27	0.05	-0.07	-0.08	0.27	0.42	-0.43	0.58	0.4	-0.05	0.49	0.35	-0.48	0.43	0.36	0.2	0.04	0.63		0.05
Other Liab	0.75	0.41	0.66	0.43	0.81	0.14	-0.19	0.18	0.25	0.71	0.87	0.73	0.61	0.7	0.4	0.45	0.35	0.55	0.6	0.71	0.65	0.53	0.36	0.12	0.05

Click cells to compare fundamentals

Molecular Templates Account Relationship Matchups

Molecular Templates fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	174.2M	139.9M	192.4M	97.5M	35.4M	33.6M
Other Current Liab	2.5M	20.4M	12.1M	8.8M	4.3M	6.7M
Total Current Liabilities	35.8M	37.6M	46.7M	57.1M	17.3M	19.2M
Total Stockholder Equity	103.0M	59.3M	65.7M	(15.1M)	4.2M	4.0M
Property Plant And Equipment Net	28.1M	33.4M	27.9M	25.8M	16.6M	17.4M
Net Debt	(70.8M)	1.9M	20.1M	18.4M	707K	742.4K
Retained Earnings	(164.1M)	(269.0M)	(352.1M)	(444.8M)	(452.9M)	(430.2M)
Accounts Payable	1.5M	2.4M	1.6M	504K	1.5M	1.3M
Cash	85.5M	25.2M	25.0M	32.2M	11.5M	10.9M
Non Current Assets Total	34.3M	38.6M	44.1M	29.3M	18.6M	13.4M
Non Currrent Assets Other	4.7M	5.2M	7.2M	3.5M	142.0K	134.9K
Cash And Short Term Investments	125.1M	93.9M	143.0M	61.0M	11.5M	10.9M
Common Stock Shares Outstanding	2.5M	3.2M	3.7M	3.8M	4.5M	4.7M
Short Term Investments	0.0	10.2M	39.6M	68.7M	118.1M	28.9M
Liabilities And Stockholders Equity	174.2M	139.9M	192.4M	97.5M	35.4M	33.6M
Non Current Liabilities Total	35.4M	43.0M	80.0M	55.6M	13.8M	13.2M
Other Current Assets	489K	7.2M	5.2M	7.2M	5.0M	4.0M
Other Stockholder Equity	267.1M	328.3M	417.7M	429.7M	457.1M	267.9M
Total Liab	71.2M	80.5M	126.7M	112.7M	31.2M	51.2M
Property Plant And Equipment Gross	28.1M	22.3M	27.9M	25.8M	43.6M	45.8M
Total Current Assets	139.9M	101.3M	148.2M	68.3M	16.8M	15.9M
Accumulated Other Comprehensive Income	18K	17K	(48K)	(66K)	(75.9K)	(79.7K)
Short Long Term Debt Total	17.5M	27.1M	45.1M	50.6M	12.2M	14.4M
Current Deferred Revenue	17.3M	14.8M	32.9M	45.6M	9.0M	14.1M
Short Term Debt	14.5M	2.2M	2.6M	2.2M	2.5M	2.8M
Common Stock Total Equity	27K	37K	46K	50K	64.4K	47.9K
Common Stock	27K	37K	46K	50K	5K	4.8K
Other Liab	20.8M	15.8M	35.0M	7.2M	8.3M	9.9M
Net Tangible Assets	103.0M	59.3M	65.7M	(15.1M)	(17.4M)	(16.5M)
Other Assets	3.5M	5.2M	7.2M	3.5M	1.0	0.95
Long Term Debt	2.9M	14.9M	35.5M	36.2M	41.6M	43.7M
Retained Earnings Total Equity	(94.7M)	(164.1M)	(269.0M)	(352.1M)	(404.9M)	(425.1M)
Capital Surpluse	195.6M	267.1M	328.3M	417.7M	480.4M	333.7M
Deferred Long Term Liab	2.7M	19.4M	4.5M	33.4M	30.0M	19.0M
Non Current Liabilities Other	13.0M	8.2M	11.2M	1.3M	4.1M	7.7M
Intangible Assets	1.3M	1.2M	1.1M	700K	600K	570K
Property Plant Equipment	18.2M	33.4M	19.3M	25.8M	29.6M	31.1M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Molecular Templates is a strong investment it is important to analyze Molecular Templates' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Molecular Templates' future performance. For an informed investment choice regarding Molecular Stock, refer to the following important reports:

How To Invest In Molecular

Details

Is Molecular Stock a good investment?

Details

What is Molecular Templates' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Templates. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Molecular Stock, please use our How to Invest in Molecular Templates guide.

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Templates. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Templates listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.97)

Earnings Share

(3.05)

Revenue Per Share

4.544

Quarterly Revenue Growth

(0.92)

Return On Assets

(0.38)

The market value of Molecular Templates is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Templates' value that differs from its market value or its book value, called intrinsic value, which is Molecular Templates' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Templates' market value can be influenced by many factors that don't directly affect Molecular Templates' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Molecular Templates' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Templates is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Templates' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Molecular Net Working Capital vs Net Receivables Analysis

Net Working Capital vs Net Receivables

Net Working Capital vs Net Receivables Correlation Analysis

Correlation Coefficient

Net Working Capital

Net Receivables

Molecular Templates fundamental ratios Correlations

Molecular Templates Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Molecular Templates fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Total Assets
Property Plant And Equipment Gross	+ 0.97	Common Stock Shares Outstanding
Total Liab	+ 0.95	Non Current Liabilities Total
Current Deferred Revenue	+ 0.93	Total Current Liabilities

Other Stockholder Equity	- 0.89	Retained Earnings
Cash	- 0.85	Net Debt
Common Stock Total Equity	- 0.83	Retained Earnings
Net Debt	- 0.68	Total Stockholder Equity
Retained Earnings	- 0.67	Net Debt
Short Term Debt	- 0.54	Net Debt